Mereo BioPharma Group (MREO) Competitors $1.74 -0.03 (-1.41%) As of 02:20 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock MREO vs. UPB, SION, ORIC, PHAR, SYRE, SPRY, PRAX, QURE, ATAI, and CRONShould you be buying Mereo BioPharma Group stock or one of its competitors? The main competitors of Mereo BioPharma Group include Upstream Bio (UPB), Sionna Therapeutics (SION), Oric Pharmaceuticals (ORIC), Pharming Group (PHAR), Spyre Therapeutics (SYRE), ARS Pharmaceuticals (SPRY), Praxis Precision Medicines (PRAX), uniQure (QURE), atai Life Sciences (ATAI), and Cronos Group (CRON). These companies are all part of the "pharmaceutical products" industry. Mereo BioPharma Group vs. Its Competitors Upstream Bio Sionna Therapeutics Oric Pharmaceuticals Pharming Group Spyre Therapeutics ARS Pharmaceuticals Praxis Precision Medicines uniQure atai Life Sciences Cronos Group Upstream Bio (NASDAQ:UPB) and Mereo BioPharma Group (NASDAQ:MREO) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, profitability, earnings, analyst recommendations, media sentiment, institutional ownership and dividends. Which has better earnings and valuation, UPB or MREO? Mereo BioPharma Group has lower revenue, but higher earnings than Upstream Bio. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioUpstream Bio$2.37M372.48-$62.81MN/AN/AMereo BioPharma Group$500K554.91-$43.25M-$0.07-24.93 Does the media prefer UPB or MREO? In the previous week, Upstream Bio had 3 more articles in the media than Mereo BioPharma Group. MarketBeat recorded 3 mentions for Upstream Bio and 0 mentions for Mereo BioPharma Group. Upstream Bio's average media sentiment score of 0.22 beat Mereo BioPharma Group's score of 0.00 indicating that Upstream Bio is being referred to more favorably in the media. Company Overall Sentiment Upstream Bio Neutral Mereo BioPharma Group Neutral Do analysts rate UPB or MREO? Upstream Bio presently has a consensus price target of $56.50, suggesting a potential upside of 245.04%. Mereo BioPharma Group has a consensus price target of $7.40, suggesting a potential upside of 324.07%. Given Mereo BioPharma Group's stronger consensus rating and higher probable upside, analysts plainly believe Mereo BioPharma Group is more favorable than Upstream Bio.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Upstream Bio 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00Mereo BioPharma Group 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.20 Is UPB or MREO more profitable? Mereo BioPharma Group has a net margin of 0.00% compared to Upstream Bio's net margin of -3,836.58%. Upstream Bio's return on equity of -35.90% beat Mereo BioPharma Group's return on equity.Company Net Margins Return on Equity Return on Assets Upstream Bio-3,836.58% -35.90% -26.26% Mereo BioPharma Group N/A -80.00%-66.94% Do institutionals & insiders hold more shares of UPB or MREO? 62.8% of Mereo BioPharma Group shares are owned by institutional investors. 13.6% of Upstream Bio shares are owned by company insiders. Comparatively, 5.5% of Mereo BioPharma Group shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. SummaryMereo BioPharma Group beats Upstream Bio on 7 of the 13 factors compared between the two stocks. Get Mereo BioPharma Group News Delivered to You Automatically Sign up to receive the latest news and ratings for MREO and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MREO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MREO vs. The Competition Export to ExcelMetricMereo BioPharma GroupMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$277.46M$3.13B$5.77B$10.40BDividend YieldN/A2.37%5.74%4.63%P/E Ratio-24.9320.9177.0026.77Price / Sales554.91385.22497.21161.41Price / CashN/A45.3237.1760.63Price / Book4.479.7013.736.40Net Income-$43.25M-$53.02M$3.29B$271.62M7 Day Performance-5.68%1.22%1.07%2.89%1 Month Performance6.40%7.94%6.35%9.66%1 Year Performance-59.23%10.40%81.07%31.48% Mereo BioPharma Group Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MREOMereo BioPharma Group1.6999 of 5 stars$1.75-1.4%$7.40+324.1%-58.1%$277.46M$500K-24.9340UPBUpstream Bio1.6115 of 5 stars$18.73-6.2%$56.50+201.7%N/A$1.08B$2.37M0.0038SIONSionna Therapeutics2.9354 of 5 stars$21.62-9.9%$38.00+75.8%N/A$1.06BN/A0.0035High Trading VolumeORICOric Pharmaceuticals4.5265 of 5 stars$10.50-3.5%$17.29+64.6%+3.1%$1.06BN/A-5.5680Positive NewsPHARPharming Group2.3054 of 5 stars$14.80-3.0%$30.00+102.7%+77.2%$1.05B$297.20M-113.85280Gap UpSYRESpyre Therapeutics2.6114 of 5 stars$16.63-2.2%$53.40+221.1%-47.1%$1.03B$890K-4.8973Analyst ForecastSPRYARS Pharmaceuticals2.6348 of 5 stars$10.70+6.3%$32.50+203.7%-29.3%$995.18M$89.15M-21.8490Gap UpPRAXPraxis Precision Medicines2.3326 of 5 stars$40.75-13.0%$85.88+110.7%-23.8%$985.99M$8.55M-3.32110Analyst ForecastHigh Trading VolumeQUREuniQure2.764 of 5 stars$17.43-2.9%$37.45+114.9%+155.9%$984.86M$27.12M-4.45500News CoverageATAIatai Life Sciences3.2836 of 5 stars$4.52-1.1%$11.25+148.9%+280.6%$979.53M$2.31M-6.5580News CoverageCRONCronos Group2.2714 of 5 stars$2.48-0.8%N/A+17.6%$957.23M$117.61M49.60450 Related Companies and Tools Related Companies UPB Competitors SION Competitors ORIC Competitors PHAR Competitors SYRE Competitors SPRY Competitors PRAX Competitors QURE Competitors ATAI Competitors CRON Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MREO) was last updated on 9/19/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mereo BioPharma Group plc - Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Mereo BioPharma Group With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
